参考文献/References:
[1]Zhu H, Bai T, Tian Z, et al. A clinicopathological study of 39 cases of atypical polypoid adenomyoma of the uterus. Gynecol Obstet Clin Med,2021,1:138-143.
[2]王欣,金佟,郭银树.子宫非典型息肉样腺肌瘤49例临床分析.中国微创外科杂志,2020,20(10):887-890.
[3]Ma B, Zhu Y, Liu Y. Management of atypical polypoid adenomyoma of the uterus: A single center’s experience. Medicine,2018,97:e0135.
[4]Raffone A, Travaglino A, Saccone G, et al. Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review. Acta Obstet Gynecol Scand,2019,98:842-855.
[5]Wang X, Guo Y. Clinical analysis of 44 cases of atypical polypoid adenomyoma of the uterus. BMC Womens Health,2022,22(1):60.
[6]Kihara A, Amano Y, Yoshimoto T, et al. Stromal p16 expression helps distinguish atypical polypoidadenomyoma from myoinvasiveendometrioid carcinoma of the uterus. Am J Surg Pathol,2019,43:1526-1535.
[7]Lu B, Yu M, Shi H, et al. Atypical polypoid adenomyoma of the uterus: A reappraisal of the clinicopathological and immunohistochemical features. Pathol Res Pract,2019,215:766-771.
[8]Kathrin HA, Brambs CE, Hill Er G, et al. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd,2021,81:1145-1153.
[9]Travaglino A, Raffone A, Saccone G, et al. Immunophenotype of atypical polypoid adenomyoma of the uterus: Diagnostic value and insight on pathogenesis. Appl Immunohistochem Mol Morphol,2020,28:646-653.
[10]McCluggage WG, Van de Vijver K. SATB2 is consistently expressed in squamous morules associated with endometrioid proliferative lesions and in the stroma of atypical polypoid adenomyoma. Int J Gynecol Pathol,2019,38:397-403.
[11]Travaglino A, Raffone A, Gencarelli A, et al. Significance of stromal markers in atypical polypoid adenomyoma. Pathol Res Pract,2020,216:153133.
[12]Mikos T, Tsolakidis D, Grimbizis GF. Clinical presentation and management of atypical polypoid adenomyomas: Systematic review of the literature. Eur J Obstet Gynecol Reprod Biol,2019,236:14-21.
[13]Němejcová K, Kenny SL, Laco J, et al. Atypical polypoid adenomyoma of the uterus: an immunohistochemical and molecular study of 21 cases. Am J Surg Pathol,2015,39:1148-1155.
[14]Raffone A, Travaglino A, Saccone G, et al. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and metaanalysis. Acta Obstet Gynecol Scand,2019,98:275-286.
[15]Travaglino A, Raffone A, Saccone G, et al. Immunohistochemical nuclear expression of βcatenin as a surrogate of CTNNB1 Exon 3 mutation in endometrial cancer. Am J Clin Pathol,2019,151:529-538.
[16]Longacre TA, Chung MH, Rouse RV, et al. Atypical polypoidadenomyofibromas (atypical polypoidadenomyomas) of the uterus. A clinicopathologic study of 55 cases. Am J Surg Pathol,1996,20(1):1-20.
[17]Di Spiezio Sardo A, Mazzon I, Gargano V, et al. Hysteroscopic treatment of atypical polypoid adenomyoma diagnosed incidentally in a young infertile woman. Fertil Steril,2008,89(2):456.e9-e12.
[18]Nomura H, Sugiyama Y, Tanigawa T, et al. Longterm outcomes of fertilitysparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate. Arch Gynecol Obstet,2016,293:177-181.